L-Methylfolate

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: mood energy focus

Research Overview

Research on L-methylfolate (5-methyltetrahydrofolate) has been most extensively studied in psychiatry—particularly as an adjunctive treatment for major depressive disorder (MDD), including SSRI-resistant depression—and more recently in ophthalmology and microvascular disease contexts where homocysteine and oxidative stress are implicated (e.g., diabetic retinopathy and neovascular age-related macular degeneration). Mechanistic work and narrative reviews commonly emphasize L-methylfolate’s role in one-carbon metabolism and methylation capacity, with downstream relevance to monoamine synthesis, folate–homocysteine balance, immune/inflammatory signaling, glutamatergic/NMDA-related pathways, and potentially gut microbiome interactions. Systematic reviews spanning multiple psychiatric conditions (e.g., schizophrenia, bipolar disorder, autism spectrum disorder, ADHD) suggest a recurring signal of benefit, but the evidence base is uneven across diagnoses and study designs.

The strongest clinical evidence in the provided abstracts supports L-methylfolate as an adjunct to antidepressant therapy in a subset of patients with MDD who have an inadequate response to SSRIs, with one multicenter sequential parallel comparison trial showing significant benefit at 15 mg/day (including a clinically meaningful response advantage and good tolerability comparable to placebo), whereas a lower-dose/step-up regimen did not separate from placebo. In ophthalmology, early clinical evidence (small, non-blinded comparative study) suggests that a vitamin formulation containing L-methylfolate can reduce elevated homocysteine and retinal venous pressure when added to anti-VEGF therapy in neovascular AMD, with associated favorable anatomic/clinical signals; however, these findings reflect combination supplementation rather than isolated L-methylfolate effects. Across areas, tolerability is generally reported as favorable, but efficacy appears context- and dose-dependent and may be moderated by baseline nutritional status or metabolic factors.

Key gaps include the need for larger, well-powered randomized controlled trials that (i) clarify optimal dosing, duration, and patient selection in depression (including biomarker- or genotype-stratified approaches such as folate status, homocysteine, and MTHFR or other one-carbon pathway variants), (ii) determine whether L-methylfolate has standalone antidepressant efficacy versus primarily augmentation effects, and (iii) extend outcomes to relapse prevention and suicidality with rigorous measurement. In retinal and microvascular disease, more definitive trials are needed to isolate the contribution of L-methylfolate from multi-nutrient formulations, establish clinically meaningful endpoints (vision outcomes, injection burden, progression metrics), and confirm mechanisms linking homocysteine lowering and oxidative stress modulation to disease modification. Across indications, standardization of formulations, baseline deficiency assessment, and reproducible biomarker-driven responder analyses remain important priorities for advancing the field.

1. What conditions has L-Methylfolate been studied for?

  • Major depressive disorder (MDD), especially as adjunctive therapy in patients with partial or no response to SSRIs (two multicenter randomized trials; plus a post hoc biomarker/genetic analysis).

  • Other psychiatric disorders (systematic review across conditions): postpartum and post-menopausal depression, schizophrenia, autism spectrum disorder, ADHD, and bipolar disorder (evidence base includes randomized and open-label trials; the review notes the most consistent findings with levomefolic acid/5-methylfolate).

  • Schizophrenia specifically: a randomized, double-blind trial of L-methylfolate 15 mg for 12 weeks in outpatients on stable antipsychotics (primary outcome: plasma methylfolate; secondary: symptoms, cognition, MRI measures).

  • Diabetic peripheral neuropathy (type 2 diabetes): studied as part of a combination product containing L-methylfolate + methylcobalamin (B12) + pyridoxal-5’-phosphate (B6) in a 24-week randomized placebo-controlled trial.

  • Diabetic retinopathy (DR): discussed in a review as part of nutritional strategies targeting homocysteine and oxidative stress, including in the context of MTHFR polymorphisms.

  • Neovascular age-related macular degeneration (nAMD): studied as part of a vitamin preparation containing L-methylfolate (Ocufolin forte) added to anti-VEGF therapy, assessing homocysteine, retinal venous pressure, and ocular outcomes.

  • Suicidality in depression: mentioned as a target of interest in a narrative review of folate-related compounds, but the abstracts provided do not describe a dedicated clinical trial with suicidality as a primary endpoint.

2. Does it work in treating those conditions? Summarize the evidence.

  • MDD (SSRI-resistant; adjunctive use): Evidence is mixed by dose. In two sequential parallel comparison design trials, the trial that used 15 mg/day throughout found significantly greater efficacy for adjunctive L-methylfolate vs SSRI + placebo on primary outcomes (response rate and symptom score change) and some secondary measures; number needed to treat (NNT) ≈ 6. The other trial (7.5 mg/day for 30 days then 15 mg/day) found no significant difference between groups.

  • MDD (who benefits most): A post hoc analysis of the 15 mg/day SSRI-resistant trial reported that patients with certain baseline biological markers (e.g., BMI ≥ 30, elevated inflammatory/oxidative stress markers, low SAMe/SAH ratio) and certain genetic markers had greater improvement with L-methylfolate vs placebo. This is hypothesis-generating; the authors note confirmatory studies are needed.

  • Schizophrenia: A randomized, double-blind trial (12 weeks, 15 mg/day) evaluated physiological and clinical effects. The abstract emphasizes the rationale (folate-pathway variants can limit folic acid conversion; L-methylfolate is bioactive) and lists symptom/cognition/MRI outcomes, but the provided text is truncated before reporting clinical efficacy results. From the abstract as given, we can only conclude it was studied and designed to assess both biological and clinical endpoints; clinical benefit cannot be confirmed from the excerpt provided.

  • Diabetic peripheral neuropathy (combination with B12 and B6): In a 24-week randomized placebo-controlled trial (n=214), the combination did not significantly improve the primary objective measure (vibration perception threshold), but did show symptomatic improvement on NTSS-6 at weeks 16 and 24 (P=.013 and P=.033 vs placebo) and improved quality-of-life measures. Because this was a combination product, the specific contribution of L-methylfolate alone cannot be isolated from this trial.

  • nAMD (Ocufolin forte + anti-VEGF): In a small comparative study (27 patients), adding Ocufolin forte was associated with a larger reduction in homocysteine (−5.58 μmol/L vs −0.57) and retinal venous pressure (−4.60 mmHg vs −0.75) over ~4 months, with reported favorable influence on morphology and future treatment intervals. Limitations include small sample size and use of a multi-ingredient product, so causality and the specific role of L-methylfolate are uncertain.

  • Diabetic retinopathy: The DR abstract is a review proposing nutritional strategies (including L-methylfolate among many nutrients) to address homocysteine/oxidative stress and cofactor deficiencies. It is supportive but not definitive clinical trial evidence for L-methylfolate as a stand-alone treatment.

  • Across psychiatric disorders (systematic review): The PRISMA systematic review (23 studies) concludes there is increasing evidence that folate supplements—especially levomefolic acid/5-methylfolate—may improve outcomes in several psychiatric conditions, particularly as adjunct pharmacotherapy, and are well tolerated. However, the review includes heterogeneous designs (randomized and open-label) and conditions, which limits certainty and generalizability.

3. What health benefits does it have?

  • Adjunctive antidepressant benefit in SSRI-resistant MDD (dose-dependent): In one multicenter trial, 15 mg/day adjunctive L-methylfolate improved response and symptom severity compared with placebo augmentation (NNT ≈ 6).

  • Potential “targeted” benefit in subgroups with inflammation/metabolic issues: Post hoc data suggest greater antidepressant response in patients with markers such as obesity and elevated inflammatory/oxidative stress biomarkers, and in certain folate-pathway genotypes (requires confirmation).

  • Homocysteine lowering: In the diabetic neuropathy combination trial, homocysteine decreased by 2.7 ± 3.0 μmol/L vs an increase with placebo. In nAMD, the Ocufolin group had a larger homocysteine reduction (−5.58 μmol/L vs −0.57). These findings support an effect on one-carbon metabolism/homocysteine balance, though both studies used multi-ingredient formulations.

  • Possible ocular microvascular/pressure-related benefits (preliminary): In nAMD, adding Ocufolin forte reduced retinal venous pressure more than control and was associated with favorable morphological/treatment-interval signals (preliminary; small study; multi-ingredient).

  • Symptom relief in diabetic neuropathy (with B12 and B6): Improved patient-reported neuropathy symptoms (NTSS-6) and quality-of-life measures despite no change in vibration perception threshold.

  • Mechanistic plausibility in mood regulation: The narrative review links folate-related pathways to the one-carbon cycle, immune function, glutamatergic/NMDA-related excitation, and gut microbiome eubiosis—supporting biological plausibility, though these are not direct proof of clinical benefit.

4. Does it have any downsides or side effects?

  • Generally well tolerated in the MDD augmentation trial: Adjunctive L-methylfolate (15 mg/day) was reported as well tolerated, with adverse event rates no different from placebo in that study.

  • Low adverse-event frequency in the diabetic neuropathy combination trial: Adverse events were infrequent, with no single event occurring in ≥2% of subjects (again, this was a combination product, not L-methylfolate alone).

  • Evidence limitations (a “downside” for decision-making): Several findings come from reviews, post hoc analyses, small studies, or multi-ingredient formulations, which makes it harder to attribute benefits/risks specifically to L-methylfolate and to predict who will respond.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

  • Potential benefit in folate-pathway genetic variants: The schizophrenia abstract notes that folic acid’s modest benefit can be limited by common folate-pathway variants that reduce conversion to active folate; L-methylfolate is the bioactive form and is therefore mechanistically positioned to bypass some conversion bottlenecks.

  • Genetic markers predicting antidepressant response (post hoc): In SSRI-resistant MDD, a post hoc analysis found that certain genomic markers associated with L-methylfolate synthesis and metabolism (and combinations of genetic + biological markers) were linked to greater symptom reduction with adjunctive L-methylfolate 15 mg vs placebo. This suggests pharmacogenomic stratification may be useful, but the authors explicitly call for confirmatory studies.

  • MTHFR polymorphisms (ocular disease risk context): The diabetic retinopathy review highlights that MTHFR polymorphisms can increase homocysteine and DR risk/severity, and proposes addressing these metabolic issues (including with L-methylfolate among other nutrients). This supports a rationale for benefit in people with MTHFR variants, but it is presented as a review-based strategy rather than definitive genotype-stratified trial proof.

  • Evidence of harm in specific genotypes: None of the provided abstracts report genotype-specific harm signals from L-methylfolate; however, absence of evidence here is not proof of absence, and genotype-stratified safety data are limited in the excerpts provided.

References

  1. Folate and Its Significance in Depressive Disorders and Suicidality: A Comprehensive Narrative Review.
    Timur Liwinski, Undine E Lang (2023) - Nutrients
  2. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials.
    George I Papakostas, Richard C Shelton, John M Zajecka, Bijan Etemad, Karl Rickels, Alisabet Clain, Lee Baer, Elizabeth D Dalton, Garret R Sacco, David Schoenfeld, Michael Pencina, Allison Meisner, Teodoro Bottiglieri, Erik Nelson, David Mischoulon, Jonathan E Alpert, James G Barbee, Sidney Zisook, Maurizio Fava (2012) - The American journal of psychiatry
  3. The potential use of folate and its derivatives in treating psychiatric disorders: A systematic review.
    Nelson Siu Kei Lam, Xin Xin Long, Xuegang Li, Mirette Saad, Florence Lim, James Cg Doery, Robert C Griffin, Cherrie Galletly (2022) - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  4. Nutritional and medical food therapies for diabetic retinopathy.
    Ce Shi, Peng Wang, Shriya Airen, Craig Brown, Zhiping Liu, Justin H Townsend, Jianhua Wang, Hong Jiang (2020) - Eye and vision (London, England)
  5. The effect of a specific vitamin supplement containing L-methylfolate (Ocufolin forte) in patients with neovascular age-related macular degeneration.
    Tatjana Josifova, Katarzyna Konieczka, Andreas Schötzau, Josef Flammer (2025) - Advances in ophthalmology practice and research
  6. Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial.
    George I Papakostas, Richard C Shelton, John M Zajecka, Teodoro Bottiglieri, Joshua Roffman, Clair Cassiello, Stephen M Stahl, Maurizio Fava (2014) - The Journal of clinical psychiatry
  7. Metanx in type 2 diabetes with peripheral neuropathy: a randomized trial.
    Vivian A Fonseca, Lawrence A Lavery, Tina K Thethi, Yahya Daoud, Cyrus DeSouza, Fernando Ovalle, Douglas S Denham, Teodoro Bottiglieri, Peter Sheehan, Julio Rosenstock (2013) - The American journal of medicine
  8. Biochemical, physiological and clinical effects of l-methylfolate in schizophrenia: a randomized controlled trial.
    J L Roffman, L J Petruzzi, A S Tanner, H E Brown, H Eryilmaz, N F Ho, M Giegold, N J Silverstein, T Bottiglieri, D S Manoach, J W Smoller, D C Henderson, D C Goff (2018) - Molecular psychiatry
  9. Case series of retinal vein occlusions showing early recovery using oral l-methylfolate.
    Steven Baker, Dylan Baker, Robert Baker, Craig J Brown (2024) - Therapeutic advances in ophthalmology
  10. Association of obesity and inflammatory marker levels on treatment outcome: results from a double-blind, randomized study of adjunctive L-methylfolate calcium in patients with MDD who are inadequate responders to SSRIs.
    Richard C Shelton, Michael J Pencina, Lori W Barrentine, Juan A Ruiz, Maurizio Fava, John M Zajecka, George I Papakostas (2015) - The Journal of clinical psychiatry
  11. Systematic Review and Meta-Analysis of L-Methylfolate Augmentation in Depressive Disorders.
    Abdullah Al Maruf, Ethan A Poweleit, Lisa C Brown, Jeffrey R Strawn, Chad A Bousman (2022) - Pharmacopsychiatry
  12. Metanx and early stages of diabetic retinopathy.
    Haitao Liu, Jie Tang, Chieh Allen Lee, Timothy S Kern (2015) - Investigative ophthalmology & visual science
  13. Safety evaluation of calcium L-methylfolate.
    K E Niederberger, I Dahms, T H Broschard, R Boehni, R Moser (2019) - Toxicology reports
  14. Assessing Effects of l-Methylfolate in Depression Management: Results of a Real-World Patient Experience Trial.
    Richard C Shelton, J Sloan Manning, Lori W Barrentine, Eleanor V Tipa (2013) - The primary care companion for CNS disorders
  15. Improving diabetic and hypertensive retinopathy with a medical food containing L-methylfolate: a preliminary report.
    Jianhua Wang, Craig Brown, Ce Shi, Justin Townsend, Giovana Rosa Gameiro, Peng Wang, Hong Jiang (2019) - Eye and vision (London, England)
  16. L-Methylfolate For Bipolar I depressive episodes: An open trial proof-of-concept registry.
    Andrew A Nierenberg, Rebecca Montana, Gustavo Kinrys, Thilo Deckersbach, Steven Dufour, Ji Hyun Baek (2017) - Journal of affective disorders
  17. A pilot study to assess the effect of a three-month vitamin supplementation containing L-methylfolate on systemic homocysteine plasma concentrations and retinal blood flow in patients with diabetes.
    Doreen Schmidl, Kinga Howorka, Stephan Szegedi, Kristina Stjepanek, Stefan Puchner, Ahmed Bata, Ulrike Scheschy, Gerold Aschinger, René M Werkmeister, Leopold Schmetterer, Gerhard Garhofer (2020) - Molecular vision
  18. L-methylfolate Augmentation to Antidepressants for Adolescents with Treatment-Resistant Depression: A Case Series.
    Lauren L Dartois, Danielle L Stutzman, MaryAnn Morrow (2019) - Journal of child and adolescent psychopharmacology
  19. Good, better, best: clinical scenarios for the use of L-methylfolate in patients with MDD.
    Rakesh Jain, Sloan Manning, Andrew J Cutler (2020) - CNS spectrums
  20. Brain Uptake of Folate Forms in the Presence of Folate Receptor Alpha Antibodies in Young Rats: Folate and Antibody Distribution.
    Natasha Bobrowski-Khoury, Jeffrey M Sequeira, Edward V Quadros (2023) - Nutrients


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!